Bone Biologics Corp Stock Piotroski F Score

BBLGW Stock  USD 60.50  0.00  0.00%   
This module uses fundamental data of Bone Biologics to approximate its Piotroski F score. Bone Biologics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Bone Biologics Corp. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Bone Biologics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Bone Biologics Altman Z Score, Bone Biologics Correlation, Bone Biologics Valuation, as well as analyze Bone Biologics Alpha and Beta and Bone Biologics Hype Analysis.
  
At this time, Bone Biologics' Net Debt To EBITDA is fairly stable compared to the past year. Cash Flow To Debt Ratio is likely to climb to 4.30 in 2024, despite the fact that Net Debt is likely to grow to (2.9 M). At this time, Bone Biologics' Tangible Book Value Per Share is fairly stable compared to the past year. Shareholders Equity Per Share is likely to climb to 11.60 in 2024, whereas Operating Cash Flow Per Share is likely to drop (38.13) in 2024.
At this time, it appears that Bone Biologics' Piotroski F Score is Unavailable. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
4.0
Piotroski F Score - Unavailable
Current Return On Assets

Negative

Focus
Change in Return on Assets

Decreased

Focus
Cash Flow Return on Assets

Negative

Focus
Current Quality of Earnings (accrual)

Improving

Focus
Asset Turnover Growth

No Change

Focus
Current Ratio Change

Increase

Focus
Long Term Debt Over Assets Change

Lower Leverage

Focus
Change In Outstending Shares

Decrease

Focus
Change in Gross Margin

No Change

Focus

Bone Biologics Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Bone Biologics is to make sure Bone is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Bone Biologics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Bone Biologics' financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities789.8 K831.4 K
Notably Down
Pretty Stable

Bone Biologics Corp F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Bone Biologics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Bone Biologics in a much-optimized way.

About Bone Biologics Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value Per Share

11.6

At this time, Bone Biologics' Book Value Per Share is fairly stable compared to the past year.

Bone Biologics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Bone Biologics from analyzing Bone Biologics' financial statements. These drivers represent accounts that assess Bone Biologics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Bone Biologics' important valuation drivers and their relationship over time.
201920202021202220232024 (projected)
Market Cap35.4M35.3M16.0M2.4M1.2M1.1M
Enterprise Value46.7M47.1M9.3M(5.1M)(1.8M)(1.7M)

Bone Biologics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bone Biologics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bone Biologics' managers, analysts, and investors.
Environmental
Governance
Social

About Bone Biologics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bone Biologics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bone Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bone Biologics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Bone Stock Analysis

When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.